{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:51:08Z","timestamp":1790470268169,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejca.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T17:53:40Z","timestamp":1625248420000},"page":"234-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-0478","authenticated-orcid":false,"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiya","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.05.005_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.005_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.005_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.005_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.005_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.005_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.005_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.005_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.005_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.005_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.005_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials","volume":"125","author":"Hauschild","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.05.005_bib12","series-title":"COMBI-AD: adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E\/K\u2013mutant melanoma. Presented at: 2017 ESMO Congress; Madrid, Spain; September 8-12","author":"Hauschild","year":"2017"},{"key":"10.1016\/j.ejca.2021.05.005_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdu529","article-title":"Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial","volume":"26","author":"Menzies","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.005_bib14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.005_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.005_bib16","doi-asserted-by":"crossref","first-page":"v543","DOI":"10.1093\/annonc\/mdz255.022","article-title":"1333P - adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting","volume":"30","author":"Grob","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.1016\/j.ejca.2021.05.005_bib17","doi-asserted-by":"crossref","first-page":"viii446","DOI":"10.1093\/annonc\/mdy289.007","article-title":"Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial","volume":"29","author":"Atkinson","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ejca.2021.05.005_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajco.12656","article-title":"Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists","volume":"12","author":"Atkinson","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.005_bib19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/CMR.0000000000000110","article-title":"Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma","volume":"24","author":"Lee","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2021.05.005_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-019-03780-y","article-title":"Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia","volume":"83","author":"Kim","year":"2019","journal-title":"Canc Chemother Pharmacol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2021.05.005_bib21","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1086\/317513","article-title":"Circulating cytokines as mediators of fever","volume":"31","author":"Netea","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:14Z","timestamp":1760733254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":21,"alternative-id":["S0959804921003038"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}